Hansi AT-B (03378) was approved to conduct clinical trials of injectable HX111 in the People's Republic of China

Zhitongcaijing · 2d ago

According to the Zhitong Finance App, Hansite-B (03378) announced that the innovative drug HX111 (HX111) for injection developed by the company has been approved by the China Drug Administration to conduct clinical trials in the People's Republic of China.

HX111 is the first (FIC) OX40 targeted antibody conjugate drug (ADC). Preclinical studies have shown that OX40 is a tumor-associated antigen (TAA), which is overexpressed in several malignant tumors (including some lymphomas) compared to normal tissues, making it an appropriate target for ADC methods such as HX111. Furthermore, OX40 is also overexpressed in regulatory T cells (Treg) in the tumor microenvironment (TME), and these Tregs are known to inhibit anti-tumor immunity. Removal of these Tregs represents a novel mechanism of action (MOA) for cancer immunotherapy. This effect can be achieved through HX111 and has potential pan-cancer application prospects.

HX111 is the third pioneering molecule advanced to clinical development by the company after HX009 and HX044, two FIC bispecific antibody (BsAb) therapies. The company will continue to work hard to bring more novel FIC drugs through clinical development and eventually bring them to market.